dc.contributor.author | Mutlu, Yaşa Gül | |
dc.contributor.author | Güvenç, Birol | |
dc.contributor.author | Serin, İstemi | |
dc.contributor.author | Balık Aydın, Berrin | |
dc.contributor.author | Alacacıoğlu, İnci | |
dc.contributor.author | Güven, Serkan | |
dc.contributor.author | Sevindik, Ömür Gökmen | |
dc.date.accessioned | 2023-03-16T11:32:44Z | |
dc.date.available | 2023-03-16T11:32:44Z | |
dc.date.issued | 2022 | en_US |
dc.identifier.citation | Mutlu, Y. G., Güvenç, B., Serin, İ., Balık Aydın, B., Alacacıoğlu, İ., Güven, S. ... Sevindik, Ö. G. (2022). Assesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort. Blood içinde (11490-11490. ss.). https://dx.doi.org/10.1182/blood-2022-165732 | en_US |
dc.identifier.issn | 0006-4971 | |
dc.identifier.issn | 1528-0020 | |
dc.identifier.uri | https://dx.doi.org/10.1182/blood-2022-165732 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/10623 | |
dc.description.abstract | Treatment free remission (TFR) is one of the main goals of therapy in Chronic Myeloid Leukemia (CML). Patient perspective and expectations have an indicative effect on discontinuation decisions. We analyzed 116 CML patients' perspective on TFR and factors that associated with willingness for tyrosine kinaz inhibitor (TKI) discontinuation from four different center in Turkey based on a national survey. Patients in our cohort had 7.8% awareness of TFR and after brief information willingness to attempt TFR has been reached to 58.9% in all population. Shorter disease duration was associated with enhanced willingness to attempt discontinuation in multivariate analyses (p=0.031). Most common patient related limitation for TKI discontinuation decision was anxiety about disease relaps and TKI resistance. Even disease relaps in TFR means molecular and detectable with close monitoring, patients still had considerable concerns about TKI discontinuation. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | American Society of Hematology | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Turkish Multicenter Cohort | en_US |
dc.subject | CML | en_US |
dc.subject | Free Remission | en_US |
dc.title | Assesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort | en_US |
dc.type | conferenceObject | en_US |
dc.relation.ispartof | Blood | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.department | İstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-6826-7818 | en_US |
dc.authorid | 0000-0001-9636-4113 | en_US |
dc.identifier.volume | 140 | en_US |
dc.identifier.issue | Supplement: 1 | en_US |
dc.identifier.startpage | 11490 | en_US |
dc.identifier.endpage | 11490 | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1182/blood-2022-165732 | en_US |
dc.institutionauthor | Balık Aydın, Berrin | |
dc.institutionauthor | Sevindik, Ömür Gökmen | |
dc.identifier.wosquality | Q1 | en_US |
dc.identifier.wos | 000893230304268 | en_US |